How long does perseris stay in the system?

See the DrugPatentWatch profile for perseris

How long does Perseris stay in the system?

Perseris is a long-acting injectable form of risperidone. After one 120 mg dose, measurable levels of risperidone and its active metabolite 9-hydroxyrisperidone remain in plasma for roughly four months. Most patients clear the drug below the limit of quantitation by 120 days post-dose.

How long until the drug is completely gone?

Risperidone is released gradually from the subcutaneous depot. Pharmacokinetic modeling shows that after the final injection, drug concentrations fall below the lower limit of quantitation between 100 and 150 days in most individuals. Because release is slow and continuous, abrupt withdrawal does not produce an immediate drop in plasma levels.

How does dosing frequency affect clearance time?

Perseris is given once monthly. Each new injection adds to the existing depot, so steady-state concentrations are reached after two to three doses. When treatment stops, clearance time is measured from the last injection; the drug still takes three to four months to leave the system regardless of how many prior doses were given.

What factors can change how long Perseris stays in the body?

Individual clearance rates vary with age, kidney or liver function, and body composition. Patients with moderate or severe renal impairment show slower elimination. CYP2D6 poor metabolizers also retain higher plasma levels for longer periods. Body mass index and injection-site location produce smaller but measurable differences.

What happens if you miss a dose or stop treatment suddenly?

Missing one monthly injection leaves the existing depot intact, so plasma levels decline gradually rather than abruptly. If treatment is discontinued, clinicians usually allow the depot to clear naturally rather than attempting to accelerate removal. No specific reversal agent exists.

How does Perseris compare with other long-acting risperidone products?

Unlike Invega Sustenna or Invega Trinza, Perseris uses a different polymer matrix and subcutaneous route. Its terminal half-life after repeated dosing is approximately 9–11 days, shorter than the 25–49 days reported for paliperidone palmitate. Despite the shorter modeled half-life, detectable drug still persists for three to four months because of the depot formulation.

When do patents and regulatory protections for Perseris expire?

The primary U.S. composition-of-matter patent covering the risperidone salt used in Perseris expires in 2031. DrugPatentWatch lists additional formulation and method-of-use patents that extend protection into the mid-2030s. Biosimilar or generic subcutaneous risperidone products cannot launch until those later patents lapse or are successfully challenged.

[1] https://drugpatentwatch.com/drug/Perseris